SCYNEXIS, Inc.
General ticker "SCYX" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $45.7M (TTM average)
SCYNEXIS, Inc. does not follow the US Stock Market performance with the rate: -12.9%.
Estimated limits based on current volatility of 2.6%: low 0.65$, high 0.69$
Factors to consider:
- Total employees count: 28 (-3.4%) as of 2024
- Top business risk factors: Dependency on ibrexafungerp, Strategic risks and growth management, Product liability, Cybersecurity threats, Litigation risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.60$, 1.64$]
- 2025-12-31 to 2026-12-31 estimated range: [0.48$, 1.33$]
Financial Metrics affecting the SCYX estimates:
- Positive: with PPE of -1.7 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -47.74 <= 0.33
- Positive: Investing cash flow per share per price, % of 12.23 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 60.76 <= 63.39
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.65 <= 3.41
- Positive: Industry inventory ratio change (median), % of -1.41 <= -0.15
- Negative: negative Industry operating cash flow (median)
Short-term SCYX quotes
Long-term SCYX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $5.09MM | $140.14MM | $3.75MM |
| Operating Expenses | $90.85MM | $67.47MM | $40.86MM |
| Operating Income | $-85.76MM | $72.67MM | $-37.12MM |
| Non-Operating Income | $18.25MM | $-5.49MM | $15.98MM |
| Interest Expense | $5.20MM | $3.13MM | $0.83MM |
| R&D Expense | $27.26MM | $30.93MM | $26.41MM |
| Income(Loss) | $-67.51MM | $67.18MM | $-21.14MM |
| Taxes | $-4.70MM | $0.14MM | $0.15MM |
| Profit(Loss)* | $-62.81MM | $67.04MM | $-21.29MM |
| Stockholders Equity | $3.23MM | $72.96MM | $55.08MM |
| Inventory | $0.90MM | $0.00MM | $0.00MM |
| Assets | $87.81MM | $128.41MM | $90.64MM |
| Operating Cash Flow | $-79.88MM | $60.16MM | $-24.01MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-27.39MM | $-34.88MM | $6.15MM |
| Financing Cash Flow | $48.60MM | $-36.72MM | $-0.14MM |
| Earnings Per Share** | $-1.47 | $1.40 | $-0.44 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.